Bisphosphonate versus non-bisphosphonate treatment for hypercalcemia of malignancy in patients with renal dysfunction

Abstract

Background:

Bisphosphonates are the backbone of treatment for hypercalcemia of malignancy (HCM). However, concern regarding their safety in patients with renal dysfunction exists. The safety and effectiveness of bisphosphonates compared to other treatment options for HCM in the setting of renal dysfunction have not been evaluated.

Methods:

A retrospective cohort analysis of adult patients with HCM and renal dysfunction defined as a creatinine clearance (CrCl) <60 mL/min who received front-line bisphosphonate versus non-bisphosphonate therapy from 1/2015 to 4/2021 was conducted. The primary endpoint was the incidence of all-grade serum creatinine (SCr) elevation from baseline by day 30 from initial HCM-directed therapy. A multivariate logistic regression was conducted to examine predictors of worsening renal function.

Results:

Of 129 patients, 111 (86%) patients received bisphosphonates and 18 (14%) received non-bisphosphonate first-line HCM-directed therapy. All-grade SCr elevation occurred similarly between bisphosphonate and non-bisphosphonate groups, 27.9% versus 27.8% respectively (p = 0.99). Receipt of bisphosphonates did not significantly impact the incidence of all-grade SCr elevation (p = 0.195) while chronic kidney disease (CKD) at baseline did (p = 0.003).

Conclusions:

Bisphosphonates appear to be as safe as non-bisphosphonate therapy in patients with baseline renal dysfunction for the treatment of HCM.

Keywords

Bisphosphonates denosumab hypercalcemia of malignancy renal dysfunction

Get full access to this article

View all access options for this article.

References

Goldner

. Cancer-related hypercalcemia. J Oncol Pract 2016; 12(5): 426–432.

Zojer

Ludwig

. Hematological emergencies. Ann Oncol 2007; 18(1): i45–i48.

Malangone

Campen

. Hypercalcemia of malignancy. J Adv Pract Oncol 2015; 6(6): 586–592.

Zagzag

Fisher

, et al. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J Clin 2018; 68(5): 377–386.

Ralston

Gallacher

Patel

, et al. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990; 112(7): 499–504.

Stewart

. Hypercalcemia associated with cancer. N Engl J Med 2005; 352(4): 373–379.

Guise

Wysolmerski

. Cancer-associated hypercalcemia. N Engl J Med 2022; 386(15): 1443–1451.

Perazella

Markowitz

. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74(11): 1385–1393.

Kyle

Yee

Somerfield

, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25(17): 2464–2472.

10.

Major

Lortholary

Hon

, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19(2): 558–567.

11.

Watkins

Rogers

Atkinson

. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency. Support Care Cancer 2015; 23(6): 1657–1662.

12.

Block

Bone

Fang

, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27(7): 1471–1479.

13.

Mousseaux

Dupont

Rafat

, et al. Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients. Ann Intensive Care 2019; 9(1): 133.

14.

Harris

Taylor

Thielke

, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42(2): 377–381.

15.

Khwaja

. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120(4): c179–c184.

16.

Zometa (package insert). East Hanover, NY: Novartis Pharmaceuticals, 2014.

17.

Palmer

Tillman

3rd Sharma

, et al. Safety of intravenous bisphosphonates for the treatment of hypercalcemia in patients with preexisting renal dysfunction. Ann Pharmacother 2021; 55(3): 303–310.

18.

Glezerman

Leboulleux

, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 2014; 99(9): 3144–3152.

19.

Morgan

Sun

Deal

, et al. Denosumab for first-line treatment of hypercalcemia associated with malignancy: retrospective analysis. J Hematol Oncol Pharm 2021; 11(3): 121–126.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.44 MB